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Abstract
Background: Meningococcal disease (MD) is notoriously difficult to diagnose in the early stages of the illness and
presents similarly to many self-limiting viral infections. This mandates a cautious approach to diagnosis and initial
management of suspected MD with many children receiving precautionary broad-spectrum intravenous antibiotics.
Despite this approach, some children are still diagnosed late. In the last 10 years, there have been advances in nucleic
acid amplification techniques, and there is now a rapid test that can detect meningococcal DNA in under 30 min. This
Loop-mediated-isothermal AMPlification (LAMP) technology may make it possible to diagnose MD at initial
presentation thereby greatly improving outcomes and minimising harms through unnecessary treatment. The aim of
this systematic review is to determine the diagnostic accuracy of LAMP technology in cases of suspected MD.
The review has been registered with PROSPERO [CRD42017078026].
Methods: To identify relevant studies, we will search MEDLINE, Embase, Web of Science, Scopus and The Cochrane
Library. In additional, we will hand-search reference lists and grey literature including contacting the manufacturers of
commercially available LAMP tests for MD for any unpublished data. Two reviewers will independently screen study
eligibility and extract data. Methodological quality will be assessed, by two authors, according to the revised tool for
the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2); any discrepancies will be resolved by a third
author. The following test characteristics will be extracted into 2 × 2 tables for all included studies: true positives, false
positives, true negatives, and false negatives. Study-specific estimates of sensitivity and specificity with 95% confidence
intervals will be displayed in forest plots. To investigate heterogeneity, we will include covariates such as age, sample
type, and study type into a bivariate random-effects model.
Discussion: This review will help determine the diagnostic accuracy of LAMP technology in diagnosing MD from
blood, CSF and throat swabs in children. The data will help to define where in the diagnostic pathway LAMP could be
useful including potential as a point-of-care test for children at first presentation.
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Background
Target condition being diagnosed
Despite successful vaccination programmes, meningo-
coccal disease (MD) remains a leading infectious cause
of septicaemia and death in children worldwide [1–5].
Early diagnosis of MD significantly improves outcomes
with reduced morbidity and mortality [4, 5]. The chal-
lenge is, however, that during the prodrome invasive
MD is indistinguishable from many self-limiting viral
infections [4–6]. This invariably leads to a very cautious
approach to the management of these children with
many receiving parenteral antibiotics pending culture
results [7]. Despite this cautious approach, children are
still being diagnosed late due to the difficulties in identi-
fying those children who are infected with MD from
those who have a simple viral illness [4, 7].
Over the years, a number of studies have explored
the value of widely available biomarkers including the
use of CRP, Procalcitonin and white cell counts in the
initial diagnosis of possible MD [8–12]. Whilst these
tests have value, none of them have the necessary
diagnostic accuracy to allow them to be used as rule
out tests at presentation [8–12].
Loop-mediated-isothermal AMPlification (LAMP) for
MD is a rapid form of PCR that targets the ctrA gene se-
quence. The ctrA gene sequence is genetically conserved
across all pathogenic (capsular) stains of the bacterium
Neisseria meningitidis that is responsible for MD [13].
This technique is faster than traditional PCR techniques
and requires much simpler equipment [13–17]. It is
possible that LAMP technology could be used as a rapid
point of care test (POCT) for the early diagnosis of MD in
children. This could be achieved through the rapid testing
of blood samples or throat swab specimens in emergency
departments, primary care facilities or pharmacies.
Clinical pathway
It is very difficult to diagnose early meningococcal disease
with current guidance recommending decision-making
based on the clinical presentation and laboratory results
[7, 12]. Unfortunately, no single biomarker, combination
of biomarkers or clinical guideline has been found to be
ideal [8–12, 18]. This has resulted in a very cautious
approach resulting in the overtreatment of many children
[8, 11, 12, 14]. Despite such a cautious approach, children
are still being diagnosed late [12].
LAMP could potentially be used at two points within
existing care pathways. Firstly at presentation to identify
early invasive meningococcal disease in children who
present with a minor illness [14]. Alternatively, LAMP
could be used in place of the current gold standard
(quantitative PCR or sterile site culture) to quickly
confirm or exclude the diagnosis allowing for a more
tailored treatment including early ambulation.
The development of LAMP technology for the diagno-
sis of early MD could therefore represent a significant
breakthrough that could alter the care of thousands of
children every year worldwide.
Why perform this review?
This systematic review is required because there are a
growing number of individual studies that have reported
on the diagnostic accuracy of LAMP technology in
diagnosing MD [13, 14, 19]. These studies have used a
similar approach; LAMP directed at the conserved CtrA
region of the bacteria Neisseria meningitidis, but in dif-
ferent populations using different specimens, i.e. blood,
CSF and throat swabs [13, 14, 19]. There are, to our
knowledge, no existing systematic reviews. This review
may help researchers and policymakers identify the most
suitable sample (blood, CSF, throat swab), and it may
help to determine the role of LAMP within the existing
diagnostic pathway.
Objectives
The objective of this systematic review is to determine
the diagnostic accuracy of LAMP technology in the
diagnosis of invasive meningococcal disease in children
(< 18 years of age).
Methods/design
We will perform a literature search for relevant studies
and then screen and select studies for inclusion against
eligibility criteria. Data extraction will be performed in
duplicate on the selected studies with meta-analysis and
report writing.
We will adhere to standards of the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA)
in reporting the findings of this review [20]. The content of
this protocol follows the Preferred Reporting Items for Sys-
tematic Review and Meta-Analysis Protocols (PRISMA-P)
recommendations [21]. (Please see the Additional file 1
for the completed PRISMA-P checklist.) This review is
registered with the International Prospective Register of
Systematic Reviews (PROSPERO) [22]. The registration
number is [CRD42017078026].
Inclusion criteria
Table 1 below outlines the inclusion criteria for this re-
view. These criteria are discussed in more detail below.
Types of studies
All prospective, retrospective and RCT studies that assess
the performance of LAMP in assessing children (< 18 years
of age) with potential invasive meningococcal disease will
be included. There are no language restrictions.
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Participants
The participants were children (< 18 years of age) with
signs or symptoms of invasive meningococcal disease.
Index tests
The index test being investigated is the LAMP test for
meningococcal DNA. For the purpose of this protocol,
this is further defined as LAMP testing specific to the
ctrA gene of Neisseria meningitidis. Index testing can be
performed using blood, cerebrospinal fluid and throat
swabs. Commercially and non-commercially available
tests will be considered.
Target conditions
Meningococcal infection (invasive meningococcal disease)
is the target condition.
Reference standards
The reference standard used to confirm the presence of
the target condition in this study is quantitative PCR to
detect Neissseria meningitidis DNA in a sterile site
sample (normally blood or CSF). A positive blood or
cerebrospinal bacterial culture of Neissseria meningitidis
will also be used. No other reference standard will be
accepted.
Exclusion criteria
Studies that only assess carriage rates in healthy children
will be excluded.
Search methods for identification of studies
Electronic search strategy
An electronic search strategy has been developed in col-
laboration with the Queen’s University Belfast Medical
Librarian (RF). To identify all prospective, retrospective
and RCTs, we will search MEDLINE, Embase, Web of
Science, Scopus and The Cochrane Library inclusive of
Cochrane Controlled Trials Register. An example Medline
search strategy is attached as Additional file 2. There are
no language restrictions for this review.
Searching other resources
In addition, we will hand-search reference lists of relevant
articles. A targeted grey literature search will include
contacting the manufacturers of commercially available
LAMP test for meningococcal disease and a search of
conference abstracts.
Data collection
Selection of studies
Two reviewers (TW, MDS) will independently screen
the study eligibility and extract data. Screening will be a
two-step process with initial title/abstract screening
followed by full-text screening. Disagreements among
reviewers will be resolved through consensus or
third-party reviewer (DF). Reports that are duplicates or
co-publications of studies will be identified. Following
full-text screening, a list of excluded studies with reasons
for exclusion will be provided in an appendix of the final
report. We will begin with screening published and
unpublished records and select those that meet the
inclusion/exclusion criteria. Our search of literature will
involve both primary studies and systematic reviews.
The latter will be used only to identify additional
primary studies.
Data extraction and management
TW and MDS will develop a data extraction form, and
this will be piloted initially to achieve a good level of
agreement between the data extractors. The following
data will be extracted in duplicate by TW and MDS:
 Study characteristics: author, year of publication,
country, design, sample size, clinical setting,
number studied, number of drop-outs with
reason, and funding source.
 Population characteristics: inclusion/exclusion
criteria and patient demographics such as age and
gender.
 LAMP testing: timing of sampling, method of
sampling (e.g. throat swab, blood or CSF), time to
result and commercial availability of the test.
 Gold standard: Quantitative PCR (e.g.TaqMan® PCR)
or sterile site bacterial culture (i.e. blood/CSF)
 Outcomes: From this 2 × 2 table, we will calculate
true positives, false positives, true negatives, and
false negatives.
Assessment of methodological quality
The risk of bias of each article will be evaluated independ-
ently by two investigators (TW, MDS) and reported ac-
cording to the Quality Assessment of Diagnostic Accuracy
Studies (QUADAS-2) tool [23]. The most likely bias will
be spectrum bias with participants not representing the
population of interest. Early MD is very difficult to
Table 1 Eligibility criteria
Study characteristics Inclusion criteria
Population Children < 18 years of age with suspected
meningococcal disease
Index tests Loop-mediated-isothermal AMPlification for
Neisseria meningitidis
Reference test Quantitative PCR and/or culture of sterile site
(blood and/or CSF) specimens
Outcomes True and false positives, true and false negatives
Study designs All prospective, retrospective and randomised
control studies that report measures of
diagnostic accuracy of Loop-mediated-
isothermal AMPlification for Neisseria meningitidis
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diagnose with typically vague and non-specific symptoms.
Depending on the population, rates of MD can vary from
1 to 33% [8–11, 14]. We are primarily interested in LAMP
testing as an early test to identify those children who will
go on to deteriorate rather than considering its use in very
unwell child in whom treatment will be given irrespective
of the test result. Studies that focus on very sick children
or studies that have an especially high rate of MD may not
reflect the target population for the routine use of this test
in the future. A commentary on this potential source of
bias will be included, and where possible, we will compare
the performance of LAMP as a diagnostic test in both low
and high prevalence populations—discussed below. Dis-
agreements between the two investigators (TW, MDS)
will be resolved by consensus or arbitration by a third
party (DF).
An assessment of publication bias will not be per-
formed. There is no evidence of publication bias in
systematic reviews of diagnostic accuracy, and methods
for detecting publication bias are unreliable when applied
to diagnostic accuracy studies [24].
Statistical analyses and evidence synthesis
We will present an overview of the available studies
summarised in two tables. The first table will summarise
the study designs, participants, index tests details, sam-
ple types and the reference standards. The second table
will summarise the details on study quality relating to
QUADAS-2.
LAMP test result data will be compared to the refer-
ence test. Data for 2 × 2 tables of index test against refer-
ence standard will be extracted from each study. The
true positive, true negative, false positive and false nega-
tive rate will be recorded. If these data are not provided,
they will be calculated from raw data wherever possible.
A summary table of evidence will be produced, and indi-
vidual studies represented using forest plots displaying
the sensitivity and specificity values of the LAMP test
with 95% confidence intervals.
Inferred statistics: LAMP testing is binary with either a
positive or negative result. There is no cutoff and the bac-
teria are either present or not. In the meta-analysis, we
will therefore use a bivariate random-effects model with
covariates such as age, sample type, disease incidence,
variations in index tests and study type included to report
summary statistics of sensitivity and specificity. This ap-
proach is recommended by the Cochrane collaboration
and is best suited for the meta-analysis of diagnostic tests
where there is no cutoff or the cutoff is very similar
between studies [24]. All analyses will be performed in
duplicate by TW and MDS using SPSS 23 and STATA.
In addition to the covariates included in the bivariate
random-effects model already discussed, we will also
perform subgroup analyses on the following groups:
 Infants (less than 1 year of age)
 Pre-school children (less than 4 years)
 School-age children (4–11 years)
 Adolescents (11–18 years)
 Sample type (throat swab, blood, CSF)
 High disease prevalence
 Low disease prevalence
Investigations of heterogeneity
We will investigate the heterogeneity by incorporating
covariates into the random-effects models as discussed
above.
Discussion
Meningococcal disease is a notoriously difficult disease to
diagnose in the early stages, and as such many children are
treated with precautionary intravenous broad-spectrum
antibiotics. Despite this approach, children are still being
diagnosed late with MD. Advances in nucleic amplification
technology mean that it is now possible to perform LAMP
testing with results being available in under 30 min. What
we do not know, however, is how these tests can be used
by clinicians in real-world situations. What is the diagnos-
tic accuracy of LAMP testing for MD and how is affected
by sample type and age of the child?
By answering these questions, we will have a better
understanding of where LAMP testing could fit into the
current clinical pathway for the diagnosis of MD. In
particular, could it be used as a rapid point of care test
to diagnose early MD, or could it have role in rapidly con-
firming diagnosis after the administration of antibiotics?
This information will be of value to policy planners and
researchers in determining where in the diagnostic path-
way for MD the LAMP test could be trialled.
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